Země: Velká Británie
Jazyk: angličtina
Zdroj: VMD (Veterinary Medicines Directorate)
Salicylic Acid, Triamcinolone Acetonide
Le Vet Beheer B.V.
QD07XB02
Salicylic Acid, Triamcinolone Acetonide
Cutaneous spray, solution
POM-V - Prescription Only Medicine – Veterinarian
Cats, Dogs
Anti Inflammatory corticosteroid
Authorized
2017-01-27
Revised: January 2022 AN: 00461/2021 & 00464/2021 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Dermanolon 1.77 mg/ml + 17.7 mg/ml cutaneous spray, solution for dogs and cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCES: Triamcinolone acetonide 1.77 mg Salicylic acid 17.7 mg For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Cutaneous spray, solution. Clear colourless solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and cats. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Symptomatic treatment of seborrhoeic dermatitis 4.3 CONTRAINDICATIONS Do not use in cases of hypersensitivity to corticosteroids, salicylic acid or to any of the excipients Do not use on cutaneous ulcers. Do not use in dogs with demodicosis. Do not administer to animals weighing less than 3.5 kg body weight. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES At the beginning of treatment, existing scale and or exfoliative debris should be removed. Hair surrounding or covering the lesions may need to be clipped to enable the veterinary medicinal product to reach the affected skin. Seborrhoeic dermatitis may be a primary disorder, but can also occur as a result of underlying disorders or disease processes (e.g. allergic disorders, endocrine disorders, neoplasia). Furthermore, infections (bacterial, parasitic or fungal) Revised: January 2022 AN: 00461/2021 & 00464/2021 Page 2 of 5 commonly occur concurrently with seborrhoeic dermatitis. Therefore it is essential to identify any underlying disease process and initiate specific treatment if considered necessary. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals As the minimum bodyweight for the treatment is 3,5 kg, this product will not be suitable for use in certain patients, such as smaller dogs and cats or those with extensive lesions. Please check maximum recommended dose in section 4.9. Systemic corticosteroid effects are possible, especially when the product is u Přečtěte si celý dokument